- Home
- KZR vs INKT Comparison
KZR vs INKT Comparison
Compare KZR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | INKT |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 57.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KZR | INKT |
|---|---|---|
| Price | $6.46 | $9.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.00 | ★ $35.00 |
| AVG Volume (30 Days) | 29.3K | ★ 149.8K |
| Earning Date | 03-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.53 | $6.66 |
| 52 Week High | $7.45 | $76.00 |
Technical Indicators
Market Signals| Indicator | KZR | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 40.74 |
| Support Level | $6.63 | $6.80 |
| Resistance Level | $7.35 | $12.64 |
| Average True Range (ATR) | 0.25 | 0.73 |
| MACD | -0.06 | -0.13 |
| Stochastic Oscillator | 12.65 | 7.98 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.